News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Yuanxin Raises $465 Million For Online Healthcare Company Miaoshou Doctor
Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations, known as Miaoshou Doctor. The company's latest round was led jointly by Sequoia Capital China and Tencent.
Read
Week In Review: Suzhou's Adagene Raises $140 Million In US IPO To Develop Oncology Drugs
Adagene, a Suzhou immunoncology biopharma, completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Adagene has a market capitalization of about $1 billion.  
Read
Week In Review: Junshi Signs $1.1 Billion Deal For US-Canada Rights To PD-1
Shanghai Junshi Bio out-licensed US-Canada rights for its anti-PD-1 antibody to Coherus Bio​ in an agreement worth up to $1.1 billion. Syapse closed a $68 million growth equity investment led by China's Ally Bridge Group
Read
Week In Review: MatriDx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
MatriDx Biotech of Hangzhou closed a $32 million Series B round to support its pathogen metagenomics devices. GenFleet Therapeutics raised $16 million in a Series B+ round for clinical trials of its two lead oncology candidates in China and the US.
Read
Week In Review: Suzhou's Adagene To Stage $125 Million IPO On NASDAQ
Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. Suzhou Sinovent completed a pre-IPO financing of at least $30 million in a round led by Oceanpine Healthcare Fund.
Read
Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1
Beijing's BeiGene out-licensed ex-China rights for tislelizumab, its anti-PD-1 antibody, to Novartis​​​ in a $2.2 billion agreement. The deal includes a $650 million upfront payment to BeiGene, plus up to $1.3 billion in regulatory milestones.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications